SCHEMBL1665307

SCHEMBL1665307

COCCOc1ccccc1C=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.81
HPGD P15428 1/20 0.81
HTT P42858 1/20 0.81
SMN1; SMN2 Q16637 1/20 0.81
PTGDR2 Q9Y5Y4 1/20 0.56
MAPT P10636 2/20 0.54
LMNA P02545 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 5/20 0.50
MEN1 O00255 3/20 0.50
RAD52 P43351 1/20 0.50
SRC P12931 1/20 0.50
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.46
TLR2 O60603 1/20 0.46
ERN1 O75460 1/20 0.46
TLR1 Q15399 1/20 0.46
TLR6 Q9Y2C9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28473484 0.95 ALDH1A1 (0.72) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL28874055 0.95 ALDH1A1 (0.72) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL2810260 0.91 ALDH1A1 (0.71) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL6914412 0.90 ALDH1A1 (1.00) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL3235018 0.88 ALDH1A1 (0.62) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL26355088 0.88 ALDH1A1 (0.62) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL28875403 0.86 ALDH1A1 (0.59) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL5434859 0.86 ALDH1A1 (0.59) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL30663744 0.86 ALDH1A1 (0.59) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL1243967 0.85 ALDH1A1 (0.68) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4545535-A1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-04-30 EP disclosed
EP-4010344-B1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-10-02 EP disclosed
CN-114206884-B Thienopyrimidine derivatives as ACC inhibitors and use thereof 吉利德科学公司 2024-07-12 CN disclosed
CN-115724706-B Method for rapidly converting aldehyde group into cyano group 中国科学院兰州化学物理研究所 2024-04-12 CN disclosed
CN-115724706-A Method for quickly converting aldehyde group into cyano group 中国科学院兰州化学物理研究所 2023-03-03 CN disclosed
CN-115108999-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-09-27 CN disclosed
CN-114920704-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-08-19 CN disclosed
EP-4010344-A1 THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2022-06-15 EP disclosed
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2022-06-07 US disclosed
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2022-06-07 US disclosed
WO-2004111000-A2 PIPERIDYL DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS ASTELLAS PHARMA INC. (JP) 2004-12-23 WO disclosed
EP-1453835-A2 ADENOSINE A 2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2004-09-08 EP disclosed
US-20030212080-A1 Adenosine A2a receptor antagonists SCHERING CORPORATION 2003-11-13 US disclosed
WO-2003048164-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2003-06-12 WO disclosed
US-5958929-A CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS SANOFI (FR) 1999-09-28 US disclosed
EP-0813534-A4 6-ARYL PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF SANOFI WINTHROP INC (US) 1998-06-10 EP disclosed
US-5736548-A CYCLIC GUANOSINE 3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; TREATING HEART FAILURE, HYPERTENSION SANOFI (FR) 1998-04-07 US disclosed
EP-0813534-A1 6-ARYL PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF SANOFI PHARMACEUTICALS, INC. (US) 1997-12-29 EP disclosed
WO-1996028448-A1 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-09-19 WO disclosed
EP-0111455-A2 Unsaturated lactones CIBA-GEIGY AG (CH) 1984-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352371-B2 Thienopyrimidine derivatives as ACC inhibitors and uses thereof ACACB, ACACA, ACAT2 ALDH1A1 103/4885HPGD 386/4885HTT 4124/4885
US-20030212080-A1 Adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ALDH1A1 630/4885HPGD 3084/4885HTT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.